Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
Not provided
Aim
The workshop provided a forum for scientific discussion to clarify appropriate design elements of clinical trials of HABP and VABP.
Contributors
Spellberg, Brad Talbot, George Infectious Diseases Society of, America American College of Chest, Physicians American Thoracic, Society Society of Critical Care, Medicine
Publication
Journal: Clinical Infectious Diseases
Volume: 51 Suppl 1
Issue:
Pages: S150 - 70
Year: 2010
DOI:
:10.1086/653065
Further Study Information
Current Stage:
Not Applicable
Date: March 2009 - April 2009
Funding source(s): This article was published as part of a supplement entitled “Workshop on Issues in the Design of Clinical Trials for Antibacterial Drugs for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia,” sponsored by the US Food and Drug Administration, Infectious Diseases Society of America, American College of Chest Physicians, American Thoracic Society, and the Society of Critical Care Medicine, with financial support from the Pharmaceutical Research and Manufacturers of America, AstraZeneca Pharmaceuticals, and Forest Pharmaceuticals.
Health Area
Disease Category: Infectious disease
Disease Name: Pneumonia (hospital-acquired), Pneumonia (ventilator-associated)
Target Population
Age Range: Unknown
Sex: Either
Nature of Intervention: Drug
Stakeholders Involved
- Clinical experts
- Regulatory agency representatives
Study Type
- COS for clinical trials or clinical research
Method(s)
- Semi structured discussion
Semi structured discussion: workshop